The IPO provides Iambic with a strong cash runway through Q4 2028, but the stock will face near-term volatility from the 180-day lock-up expiration and the significant overhang of 7.0M+ shares reserved for equity plans. Monitor upcoming clinical data readouts for IAM1363 (registrational trial initiation expected as early as 2027) and IND clearance for IAM217 and IAM-C1 as key catalysts. The $60M in non-binding indications of interest from ARK and Duquesne suggest anchor demand, but actual allocations remain uncertain.
Executive Summary
Iambic Therapeutics priced its IPO at $16.00 per share, offering 9,375,000 shares for total gross proceeds of $150.0 million. The company, a clinical-stage AI-driven drug discovery platform, will receive net proceeds of approximately $135.0 million to fund clinical development of its lead HER2 inhibitor IAM1363, advance preclinical candidates IAM217 and IAM-C1, and invest in its molecular superintelligence platform. The IPO creates a public market for the stock (Nasdaq: IAM) and provides a capital runway into Q4 2028, but existing shareholders will experience immediate and substantial dilution of $8.35 per share.
Key Financial Metrics
Key Facts
- IPO priced at $16.00 per share, raising $150.0 million in gross proceeds
- 9,375,000 shares offered; underwriters have 30-day option for 1,406,250 additional shares
- Net proceeds to company estimated at $135.0 million ($155.9 million if overallotment exercised)
- Pro forma as-adjusted cash and cash equivalents of $409.4 million
- Pro forma as-adjusted net tangible book value per share of $7.65, representing $8.35 dilution to new investors
- Lead program IAM1363 in Phase 1/1b trial; IND submitted for IAM217; IAM-C1 IND expected Q4 2026
- Company has incurred significant losses: $50.1M net loss in H1 2026, $77.3M in FY2025, $245.3M accumulated deficit
- Collaboration revenue of $12.8M in H1 2026 vs $3.9M in H1 2025, driven by Takeda and RevMed partnerships
- ARK Investment Management and Duquesne Family Office have indicated interest for up to $60M aggregate in the offering
- Lock-up period of 180 days for insiders and existing shareholders
Financial Impact
IPO raises $150M gross ($135M net) at $16.00/share. Pro forma cash position of $409.4M extends runway into Q4 2028. Immediate dilution of $8.35/share for new investors.
Risk Factors
- Immediate and substantial dilution of $8.35 per share for new investors
- No approved products; all candidates are in early clinical or preclinical stages
- Significant operating losses and accumulated deficit of $245.3M
- Dependence on partnerships for revenue; partner concentration risk
- Novel AI-driven drug discovery approach is unproven for clinical success
- Lock-up expiration after 180 days could pressure stock price
- Future capital needs beyond Q4 2028 may require additional dilutive financing
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001193125-26-422865 |
| Document: 0001193125-26-422865-index-headers.html | 0001193125-26-422865 |
| Document: 0001193125-26-422865-index.html | 0001193125-26-422865 |
| Document: 0001193125-26-422865.txt | 0001193125-26-422865 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Insider Buy | $16.01 $14.00 | ▼ −12.55% | ▼ −12.63% | $14.00 (−12.55%) |
Oct 16, 2026 11d ago | 8-K | $16.34 $14.70 | ▼ −10.04% | ▼ −9.89% | $14.00 (−14.32%) |
Oct 15, 2026 12d ago | 424B4 | $23.81 $14.26 | ▼ −40.11% | ▼ −40.20% | $14.00 (−41.20%) |
Oct 15, 2026 12d ago | EFFECT | $18.91 $14.67 | ▼ −22.42% | ▼ −21.41% | $14.00 (−25.97%) |
Oct 14, 2026 13d ago | 3 | $18.91 $14.67 | ▼ −22.42% | ▼ −21.41% | $14.00 (−25.97%) |
Oct 14, 2026 13d ago | 3 | $18.91 $14.67 | ▼ −22.42% | ▼ −21.41% | $14.00 (−25.97%) |
Oct 14, 2026 13d ago | 3 | $18.91 $14.67 | ▼ −22.42% | ▼ −21.41% | $14.00 (−25.97%) |
Oct 14, 2026 13d ago | 3 | $18.91 $14.67 | ▼ −22.42% | ▼ −21.41% | $14.00 (−25.97%) |
Oct 14, 2026 13d ago | 3 | $18.91 $14.67 | ▼ −22.42% | ▼ −21.41% | $14.00 (−25.97%) |
Oct 14, 2026 13d ago | 3 | $18.91 $14.67 | ▼ −22.42% | ▼ −21.41% | $14.00 (−25.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers